Sage Therapeutics Inc.

NASDAQ: SAGE · Real-Time Price · USD
8.68
0.00 (0.00%)
At close: Jul 30, 2025, 3:59 PM

Sage Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
81.02M 70.99M 162.7M 294.23M
Short-Term Investments
423.4M 682.19M 1.11B 1.45B
Long-Term Investments
n/a n/a 1.27M 1.27M
Other Long-Term Assets
4.28M 6.55M 69.26M 4.25M
Receivables
9.13M 83.01M 13.66M 18.51M
Inventory
n/a n/a -64.49M -18.51M
Other Current Assets
17.75M 33.16M 50.83M n/a
Total Current Assets
531.3M 869.35M 1.27B 1.8B
Property-Plant & Equipment
11.64M 6.38M 13.43M 19.13M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
15.92M 12.93M 83.95M 24.64M
Total Assets
547.22M 882.28M 1.36B 1.83B
Account Payables
12.7M 10.32M 18.95M 10.45M
Deferred Revenue
n/a n/a n/a n/a
Short-Term Debt
n/a n/a 7.64M 7.47M
Other Current Liabilities
14.84M 21.34M 35.65M 41.19M
Total Current Liabilities
71.61M 82.75M 99.26M 85.19M
Long-Term Debt
n/a n/a 4.49M 10.96M
Other Long-Term Liabilities
n/a n/a -4.39M -10.86M
Total Long-Term Liabilities
10.52M n/a 4.59M 11.06M
Total Liabilities
82.13M 82.75M 103.85M 96.26M
Total Debt
11.84M 5.17M 12.13M 18.43M
Common Stock
6K 6K 6K 6K
Retained Earnings
-2.97B -2.57B -2.03B -1.5B
Comprehensive Income
244K -814K -10.21M -2.66M
Shareholders Equity
465.09M 799.53M 1.25B 1.73B
Total Investments
423.4M 682.19M 1.11B 1.45B